Page 60 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine Refractory pulmonary adenocarcinoma

pulmonary adenocarcinoma remains a constant research https://doi.org/10.1183/09031936.00026711
challenge worldwide. It is necessary to assess patients 3. Vilhonen H, Kurki S, Laitinen T, et al., 2019, Retrospective
comprehensively and apply clinical treatment guidelines evaluation of lung adenocarcinoma patients progressing on
flexibly. In addition, further understanding and research 1 line chemotherapy. Medicina (Kaunas), 55: 743.
st
are still needed to improve the prognosis of these patients.
https://doi.org/10.3390/medicina55110743
Acknowledgments 4. Xu L, Qi Q, Zhang Y, et al., 2019, Combination of icotinib
and chemotherapy as first-line treatment for advanced lung
The authors would like to thank the participating patient, adenocarcinoma in patients with sensitive EGFR mutations:
as well as the colleagues and nurses who made this work A randomized controlled study. Lung Cancer, 133: 23–31.
possible.
https://doi.org/10.1016/j.lungcan.2019.05.008
Funding 5. Paliwal P, Rajappa S, Santa A, et al., 2017, Clinical profile
This work was supported by foundation of “Lvyang Jinfeng” and outcomes of patients with Stage IV adenocarcinoma of
talents attracting plan (LYJF00040). lung: A tertiary cancer center experience. Indian J Cancer,
54: 197–202.
Conflict of interest https://doi.org/10.4103/0019-509X.219595
There is no conflicts of interest in this study. 6. Feng Y, Tang L, Wang H, et al., 2023, Immune checkpoint
inhibitors combined with angiogenic inhibitors in
Author contributions the treatment of locally advanced or metastatic lung
adenocarcinoma patients. Cancer Immunol Immunother,
Conceptualization: Haiyan Li, Xia Lu 72: 449–459.
Investigation: All authors
Writing – original draft: Haiyan Li https://doi.org/10.1007/s00262-022-03251-z
Writing – review & editing: Haiyan Li and Xia Lu 7. Xu Z, Hao X, Lin L, et al., 2021, Concurrent chemotherapy
and first-generation epidermal growth factor receptor
Ethics approval and consent to participate (EGFR)-tyrosine kinase inhibitors (TKIs) with or without
an antiangiogenic agent as first-line treatment in advanced
Not applicable.
lung adenocarcinoma harboring an EGFR mutation. Thorac
Consent for publication Cancer, 12: 2233–2240.
https://doi.org/10.1111/1759-7714.14057
We obtained informed consent from study subjects for
publishing their data. 8. Paik SS, Hwang IK, Park MJ, et al., 2018, Pemetrexed
continuation maintenance versus conventional platinum-
Availability of data based doublet chemotherapy in EGFR-negative lung
adenocarcinoma: Retrospective analysis. Tuberc Respir Dis
The original data of the study are included in the article, (Seoul), 81: 148–155.
further inquiries can be directed to the corresponding
author. https://doi.org/10.4046/trd.2017.0090
9. Xu X, Li R, Zhu, P, et al., 2021, Clinical efficacy and safety
References of maintenance therapy for advanced non-small cell lung
cancer: A retrospective real-world study. World J Surg Oncol,
1. Moreira AL, Ocampo PSS, Xia Y, et al., 2020, A grading
system for invasive pulmonary adenocarcinoma: A proposal 19: 231.
from the international association for the study of lung https://doi.org/10.1186/s12957-021-02340-0
cancer pathology committee. J Thorac Oncol, 15: 1599–1610.
10. Oncology Society of Chinese Medical Association, Chinese
https://doi.org/10.1016/j.jtho.2020.06.001 Medical Association Publishing House, 2022, Chinese
Medical Association guideline for clinical diagnosis and
2. Travis WD, Brambilla E, Van Schil P, et al., 2011, Paradigm
shifts in lung cancer as defined in the new IASLC/ATS/ treatment of lung cancer (2022 edition). Zhonghua Zhong
ERS lung adenocarcinoma classification. Eur Respir J, Liu Za Zhi, 44: 457–490.
38: 239–243. https://doi.org/10.3760/cma.j.cn112152-20220413-00255

Volume 1 Issue 1 (2023) 4 https://doi.org/10.36922/arnm.0883